fda compounding glp-1 enforcement news today New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our FDA and Novo Nordisk Warn

El estudio descubrieron que si una persona tomaba un medicamento GLP-1, el hogar reduca su gasto en comestibles en un 5,5% en seis meses

The American Cancer Society notes that while more long-term data is needed, available evidence suggests these medications are safe regarding cancer risk

Kruse, A

But given that the intervention is simple and risk-free, experimenting with timing during a stall is reasonable

The partnership allowed patients to access NovoCare Pharmacy through the Hims & Hers platform, with a bundled offering of all dose strengths of Wegovy and a Hims & Hers membership at a single price

doi: 10.1016/j.eclinm.2024.103029 6 BhardwajS.PathakK.McLenonM.SpectorS.TuK